Dajung Kim

Busan, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

Journal: British journal of haematology

Published: March 19, 2026

A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803).

A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803).

Journal: British journal of haematology

Published: September 01, 2025

Clinical Outcomes in Patients With DLBCL Treated With R-CHOP According to Radiotherapy and Interim PET Response.

Clinical Outcomes in Patients With DLBCL Treated With R-CHOP According to Radiotherapy and Interim PET Response.

Journal: Cancer diagnosis & prognosis

Published: November 14, 2023

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170).

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170).

Journal: Frontiers in oncology

Published: April 20, 2023

A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.

A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.

Journal: Expert opinion on biological therapy

Published: February 09, 2023

Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.

Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.

Journal: Blood cancer journal

Published: August 18, 2022

Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.

Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.

Journal: Scientific reports

Published: June 17, 2021

Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation.

Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation.

Journal: The Korean journal of internal medicine

Published: December 27, 2017

Outcomes of acute kidney injury patients with and without cancer.

Outcomes of acute kidney injury patients with and without cancer.

Journal: Renal failure

Published: October 24, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026